Talk to the Veterans Crisis Line now
U.S. flag
An official website of the United States government

Health Services Research & Development

Go to the ORD website
Go to the QUERI website

HSR&D Citation Abstract

Search | Search by Center | Search by Source | Keywords in Title

Effects of positive airway pressure treatment on clinical measures of hypertension and type 2 diabetes.

Prasad B, Carley DW, Krishnan JA, Weaver TE, Weaver FM. Effects of positive airway pressure treatment on clinical measures of hypertension and type 2 diabetes. Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine. 2012 Oct 15; 8(5):481-7.

Related HSR&D Project(s)

Dimensions for VA is a web-based tool available to VA staff that enables detailed searches of published research and research projects.

If you have VA-Intranet access, click here for more information vaww.hsrd.research.va.gov/dimensions/

VA staff not currently on the VA network can access Dimensions by registering for an account using their VA email address.
   Search Dimensions for VA for this citation
* Don't have VA-internal network access or a VA email address? Try searching the free-to-the-public version of Dimensions



Abstract:

PURPOSE: Mechanistic and observational studies support an independent increase in risk of hypertension and abnormal glucose metabolism associated with obstructive sleep apnea (OSA). However, the specific populations and outcomes that improve with treatment of OSA in clinical practice are not established. We examined the effectiveness of OSA treatment on clinical blood pressure and diabetes control measures in men with preexisting systemic hypertension or type 2 diabetes. METHODS: A retrospective cohort of veterans (n = 221) with a new diagnosis of OSA and initiation of positive airway pressure treatment was identified using administrative databases and clinical records. MEASUREMENTS AND RESULTS: Outcomes were changes in blood pressure (BP; mean of 3 highest recordings; systolic and diastolic) and glycemic control (mean of 3 highest fasting glucose and hemoglobinA1C values) at 3-6 months (T1) and 9-12 months (T2) following treatment compared to pretreatment. A generalized estimating equation model was used with adjustment for potential confounders: demographics, body mass index (BMI), OSA severity, Charlson comorbidity index, and pharmacologic treatment for hypertension and diabetes. Sustained independent effects of OSA treatment (mean change [95% CI]) were noted in both systolic BP (T1; -7.44 [-10.41 to -4.47] and T2; -6.81 [-9.94 to -3.67]) and diastolic BP (T1; -3.14, [-4.99 to -1.29] and T2; -3.69, [-5.53 to -1.85]). Diabetes control measures did not change with OSA treatment. CONCLUSIONS: Treatment of OSA improves office blood pressure in hypertensive men. Prospective studies are necessary to better characterize specific populations with OSA that benefit from treatment with respect to progression of hypertension and type 2 diabetes.





Questions about the HSR&D website? Email the Web Team.

Any health information on this website is strictly for informational purposes and is not intended as medical advice. It should not be used to diagnose or treat any condition.